Israel’s BiondVax has 12,400 participants from 83 hospitals in the Phase 3 double-blind placebo-controlled trials of its Universal Flu vaccine. If successful, the new vaccine could reach pharmacies in 2023. BiondVax’s new Jerusalem facility can produce 20-40 million doses per year.

https://www.calcalistech.com/ctech/articles/0,7340,L-3775594,00.html